. 2015 Jul 21;21(27):8271–8283. doi: 10.3748/wjg.v21.i27.8271

Table 3.

Melanoma studies n (%)

Author	Type of microsphere	Type of mets (patients)	Response criteria	Response	Median OS
(publish date and study type)	(average dosage)	Type of mets (patients)	@ 1^st assessment	Response	Median OS
Xing et al[49]	SIR-Spheres	Melanoma (28)	RECIST 1.1	5/28 (21) PR	10.1 mo
(8/2014, RS)	(mean 1.86 Gbq)	13 cutaneous	@ 0.9-1.4 mo	9/28 (38) SD
		15 ocular		10/28 (42) PD
				4 lost
Memon et al[42]	Therasphere	Melanoma (16)	WHO, RECIST, and EASL	WHO	7.6 mo
(6/2014, RS)	(median 1.87 Gbq)	7 ocular	@ 0.9 mo	5 (31) CR/PR
		3 rectal		8 (50) SD
		4 cutaneous		3 (19) PD
		2 unknown		RECIST
				5 (31) CR/PR
				8 (50) SD
				3 (19) PD
				EASL
				6 (38) CR/PR
				7 (43) SD
				3 (19) PD
Gonsalves et al[37]	SIR-Spheres	Ocular melanoma (32)	RECIST 1.0	1 (3) CR	10.0 mo
(2/2011, RS)	(median 1.08 Gbq)		@ 1 mo	1 (3) PR
				18 (56) SD
				12 (38) PD
Kennedy et al[40]	SIR-Spheres	Ocular melanoma (11)	RECIST	1 (11) CR	Median OS not reached
(7/2009, RS)	(median 1.55 Gbq)		@ 1.4 mo	6 (66) PR
				1 (11) SD
				1 (11) PD
				2 lost
Reiner et al[46]	SIR-Spheres	Melanoma (2, data extracted from larger study)	RECIST 1.1	1 (50) CR/PR	None
(1/2014, PC)	(mean 1.5 Gbq)	Melanoma (2, data extracted from larger study)	@ 4 mo	1 (50) SD/PD	None
Lim et al[41]	SIR-Spheres	Ocular melanoma (1, data extracted from larger study)	RECIST	1 (100) PD	None
(4/2005, PC)	(no dosage info)	Ocular melanoma (1, data extracted from larger study)	@ 2 mo	1 (100) PD	None

PC: Prospective cohort study; RS: Retrospective study; CR: Complete response; PR: Progressive response; PD: Progressive disease; SD: Stable disease; OS: Overall survival; OR: Overall response.